Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/PH4 stock hub

FRA/PH4 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/PH4is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.5B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/PH4FRA/PH4

—

Loading chart…

In the news

Latest news · FRA/PH4

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E43

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-89.1

P25 n/aP50 n/aP75 n/a

ROIC-30.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/PH4 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

160

Groups with data

Currency

CNY

Showing 160 of 160 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Cayman Islands
Country code	DE
Employees	136
Employees Change	-4%
Employees Change Percent	-2.96
Enterprise value	EUR 1.4B
Exchange	Frankfurt Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.5B
Price	EUR 0.9
Price currency	EUR
Rev Per Employee	241,373.6x
Sic	2836
Symbol	fra/PH4
Website	https://www.cstonepharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.64%
EV Earnings	-26.12x
EV/Sales	42.69x
Forward P/E	43x
P/B ratio	19.49x
P/S ratio	44.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-154.25%
EBITDA Margin	-149.8%
Gross margin	19.01%
Gross Profit	EUR 6.2M
Gross Profit Growth Q	111.43%
Gross Profit Growth3 Y	-45.86%
Gross Profit Growth5 Y	-27.89%
Net Income	EUR -53.2M
Pretax Margin	-157.26%
Profit Margin	-162.1%
Profit Per Employee	EUR -391,275
ROA	-18.89
Roa5y	-22.36
ROCE	-49.03
ROE	-89.13
Roe5y	-78.74
ROIC	-30.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	206.36%
Cagr3y	36.86%
Cagr5y	-3.76%
Revenue Growth	-33.8x
Revenue Growth Q	43.84x
Revenue Growth3 Y	-16.1x
Revenue Growth5 Y	-10.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.2
Assets	EUR 165.4M
Cash	EUR 117.2M
Current Assets	EUR 138.8M
Current Liabilities	EUR 63.6M
Debt	EUR 42.4M
Debt Equity	EUR 0.57
Equity	EUR 75.1M
Interest Coverage	-31.33
Liabilities	EUR 90.3M
Long Term Assets	EUR 26.6M
Long Term Liabilities	EUR 26.7M
Net Cash	EUR 74.8M
Net Cash By Market Cap	EUR 5.11
Net Cash Growth	68.72%
Net Debt Equity	EUR -1
Tangible Book Value	EUR 56.9M
Tangible Book Value Per Share	EUR 0.04

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.18
Inventory Turnover	1.08
Net Working Capital	EUR -20.4M
Quick ratio	1.95
Working Capital	EUR 73.4M
Working Capital Turnover	EUR 0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-8.79%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	206.12%
200-day SMA	0.77
3Y total return	156.41%
50-day SMA	0.89
50-day SMA vs 200-day SMA	50over200
5Y total return	-17.43%
All Time High	1.98
All Time High Change	-54.55%
All Time High Date	2021-06-21
All Time Low	0.09
All Time Low Change	878.26%
All Time Low Date	2024-04-08
ATR	0.04
Ch YTD	57.9
High	0.9
High52	1.35
High52 Date	2025-09-08
High52ch	-33.33%
Low	0.9
Low52	0.28
Low52 Date	2025-05-12
Low52ch	223.74%
Ma50ch	1.6%
Price vs 200-day SMA	17.32%
RSI	42.55
RSI Monthly	60.62
RSI Weekly	57.14
Sharpe ratio	1.83x
Sortino ratio	3.19
Total Return	-8.79%
Tr YTD	57.9
Tr1m	-8.35%
Tr1w	-8.35%
Tr3m	68.22%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -50.6M
Operating margin	-154.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,195,920,567%
Net Borrowing	-1,015,439.7
Shares Insiders	1.52%
Shares Institutions	20.45%
Shares Qo Q	11.3%
Shares Yo Y	8.79%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	694.4x
Bv Per Share	0.05
Ch1m	-8.35
Ch1w	-8.35
Ch1y	206.1
Ch3m	68.22
Ch3y	156.4
Ch5y	-17.43
Ch6m	39.54
Change	-2.49%
Change From Open	0.09
Close	0.92
Days Gap	-2.58
Depreciation Amortization	1,493,609.1
Earnings Date	2026-03-26
EBIT	EUR -50.6M
EBITDA	EUR -49.2M
EPS	EUR -0.04
F Score	5
Financing CF	70,355,481
Fiscal Year End	December
Founded	2,015
Income Tax	EUR 1.6M
Investing CF	16,315,442
Is Primary Listing	0
Last Earnings Date	2026-03-26
Last Report Date	2025-12-31
Ma150	0.73
Ma150ch	23.54%
Ma20	1.03
Ma20ch	-12.37%
Net CF	44,538,416
Open	0.9
Position In Range	100
Ppne	10,364,866.7
Price Date	2026-05-08
Ptbv Ratio	25.74
Relative Volume	0.58x
Revenue	32,826,810x
SBC By Revenue	8.89x
Share Based Comp	2,918,921
Tax By Revenue	4.85x
Tr6m	39.54%
Volume	0
Z Score	-4.63

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/PH4 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/PH4 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/PH4?

Insider, institutional, and short-interest positioning.

Institutional ownership

+20.5%

Share of float held by funds and institutions

Insider ownership

+1.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+8.8%

Negative means the company is buying back shares.

Technical

FRA/PH4 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

42.6

Neutral momentum band

Price vs 200-day MA

+17.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.83

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/PH4

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/PH4 stock rating?

fra/PH4 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/PH4 analysis?

The full report lives at /stocks/fra/PH4/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/PH4?

The latest report frames fra/PH4 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/PH4 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.